174073-64-4

Basic information

• Product Name: (S)-C-PIPERIDIN-3-YL-METHYLAMINE
• Synonyms: C-PIPERIDIN-(S)-3-YL-METHYLAMINE;(S)-C-PIPERIDIN-3-YL-METHYLAMINE;(S)-Piperidin-3-ylMethanaMine
• CAS NO: 174073-64-4
• Molecular Formula: C6H14N2
• Molecular Weight: 114.19
• Mol File: 174073-64-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 176.9±8.0 °C(Predicted)
• Appearance: /
• Density: 0.897±0.06 g/cm3(Predicted)
• PKA: 10.12±0.10(Predicted)
• CAS DataBase Reference: (S)-C-PIPERIDIN-3-YL-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-C-PIPERIDIN-3-YL-METHYLAMINE(174073-64-4)
• EPA Substance Registry System: (S)-C-PIPERIDIN-3-YL-METHYLAMINE(174073-64-4)

Safety Data

• Hazardous Substances Data: 174073-64-4(Hazardous Substances Data)

Usage

General Description

(S)-C-piperidin-3-yl-methylamine is a chemical compound with a heterocyclic piperidine ring and a methylamine functional group. It is often used in the synthesis of pharmaceutical drugs and can act as a building block for various organic compounds. (S)-C-PIPERIDIN-3-YL-METHYLAMINE has potential applications in medicinal chemistry and drug discovery due to its ability to modify the bioactivity and pharmacokinetic properties of molecules. It may also be utilized as a reagent in organic synthesis, particularly in the creation of chiral compounds. Overall, (S)-C-piperidin-3-yl-methylamine has significant potential in the development of various therapeutic agents and organic compounds.

Upstream product

• 98-92-0 nicotinamide 
• 4138-26-5 nipecotamide 
• 7664-93-9 sulfuric acid 

Downstream Products

• 917107-36-9 N-{[1-(5-chloro-2-methoxybenzoyl)piperidin-3-yl]methyl}-2,2,2-trifluoroacetamide 
• 917107-35-8 N-{[1-(5-chloro-2-hydroxybenzoyl)piperidin-3-yl]methyl}-2,2,2-trifluoroacetamide 
• 1432446-27-9 C₁₉H₁₉ClN₆ 
• 74139-39-2 PtCl2(3-aminomethylpiperidine) 
• 124257-62-1 (±)-(1-benzylpiperidin-3-yl)methanamine 

Relevant articles and documents

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.